Category: Pricing

February 25, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock […]

February 12, 2021

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a […]

September 9, 2020

Democratic senators on Wednesday grilled U.S. health officials about whether President Donald Trump is interfering in the development of potential coronavirus vaccines. National Institutes of Health Director Dr. Francis Collins and U.S. Surgeon General Dr. Jerome Adams testified before the […]

July 28, 2020

With just over three months before the U.S. elections in November, President Donald Trump is making a last-ditch effort to stamp his name on a drug pricing deal that has eluded him over his first three years in office. A […]

July 21, 2020

As the world waits anxiously for more effective COVID-19 treatments and for a vaccine to halt the pandemic, analysts on all sides are examining appropriate pricing models for these critical products. Gilead’s $3000 price tag on remdesivir ($2300 for US […]

April 17, 2020

Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over […]

March 11, 2020

The FDA and the FTC said they will crack down quickly on people trying to take advantage of consumers concerned about the coronavirus infection outbreak. An “aggressive surveillance program” is monitoring social media, online marketplaces and complaints from consumers, they […]

March 9, 2020

The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters to seven companies for selling fraudulent COVID-19 products. These products are unapproved drugs that pose significant risks to patient health and violate federal law. […]

March 9, 2020

Investors have sent shares of three biopharmas zooming since Friday afternoon based on announcements that they are developing treatments for SARS-CoV-2, the virus at the center of the global COVID-19 outbreak—while a U.S./Australian biopharma today disclosed plans to advance a […]

March 4, 2020

Acthar was first approved in 1952 for the treatment of rheumatoid arthritis, but its acquisition by Questcor from the former Aventis in 2001 allowed the new owner to test out a strategy of label expansions and steep price rises. In […]

March 3, 2020

According to estimates by Transparency Market Research, the global vaccines market was worth about US$28.0 bn in 2016. As per research experts, this revenue is expected to be worth at least US$48 bn by the end of 2025. This growth […]

February 27, 2020

The new campaign comes at a critical time, as Senate Finance Committee Chairman Chuck Grassley, R-Iowa, fights to build support for his bipartisan bill to lower prescription costs. Grassley is trying to win a total of 25 Republican backers in […]